Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole (BOLERO-2)

Clinical Trial ID NCT00863655

PubWeight™ 41.74‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00863655

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2011 13.74
2 Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 2014 2.50
3 Targeted therapies for breast cancer. J Clin Invest 2011 2.22
4 Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 2011 2.10
5 Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol 2014 1.95
6 Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013 1.90
7 Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol 2016 1.83
8 Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. J Clin Oncol 2015 1.73
9 Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009 1.70
10 Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer 2013 1.26
11 Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Support Care Cancer 2013 1.05
12 Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions. Breast Cancer (Auckl) 2013 1.02
13 Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2. Breast Cancer Res Treat 2013 0.99
14 Multidrug-resistant breast cancer: current perspectives. Breast Cancer (Dove Med Press) 2014 0.99
15 PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. Onco Targets Ther 2016 0.96
16 Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget 2014 0.95
17 Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations. Horm Mol Biol Clin Investig 2012 0.92
18 Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer. Clin Adv Hematol Oncol 2013 0.87
19 The therapeutic potential of mTOR inhibitors in breast cancer. Br J Clin Pharmacol 2016 0.83
20 Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance. Clin Breast Cancer 2013 0.83
21 Soy and breast cancer: focus on angiogenesis. Int J Mol Sci 2015 0.82
22 Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Curr Med Res Opin 2013 0.82
23 Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer. Cancer Manag Res 2014 0.77
24 Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside? Int J Mol Sci 2016 0.75
Next 100